Forbes December 3, 2023
Ileus is not a good gut feeling to have. And, the U.S. Food and Drug Administration (FDA) has added ileus—which can result in intestinal blockage—as a possible serious adverse event to the Ozempic label.
As a result, the Ozempic label has joined the labels of two other glucagon-like peptide-1 (GLP-1) receptor agonists, Mounjaro and Wegovy, that have already borne warnings about ileus. At least 20 people have reported experiencing blocked intestines to the FDA’s Adverse Events Reporting System (FAERS). There have also been two deaths reported as a result. All in all, the FDA has received over 8,500 reports of gastrointestinal disorders among those using medications that contain semaglutide the main active ingredient for Ozempic.
Now, 20 people may not...
Today's Sponsors
Today's Sponsor